Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early Tuesday morning describing a phase III trial called Candor for relapsed/refractory multiple myeloma patients (RRMM), comparing (Kyprolis) carfilzomib and dexamethasone with or without Darzalex (daratumumab). The abstract #LBA-6 showed that the addition of dara decreased the risk […]
Jack Aiello
Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group.
Follow Jack on Twitter
Day 3 – “Myeloma Monday” Saving the Best for Last
Before providing details of our final full day at ASH (noting #abstract where applicable), let me review some activities from yesterday (Sunday 12/8/19). In the morning I attended a number of myeloma cancer care delivery abstracts (#383, #423, #424) where topics like diversity and racial/socioeconomic impact were discussed. Black/African-American patients are less likely to have […]
Day 1: A session full of Education Sessions, Orals, 2 special events, and one mishap
Day 1: First full day of ASH Saturday December 7, 2019 It’s nearly 11:00 p.m. as I begin to write my daily blog, but I’m still wide awake & enthusiastic, having just attended the IMF’s annual Brian D. Novis Research Grant Awards reception. After listening to some wonderful patient stories, I was encouraged to see five young […]
Day 0: Symposium Day
December 6th is actually the day before ASH officially begins, often called “Symposium” day. Today I attended the GMAN meeting and IMF Symposium. GMAN (Global Myeloma Action Network) was established about 6 years ago recognizing that Myeloma is a global disease but different countries face different issues (awareness, education, drug access, expertise) supporting myeloma patients. Our large […]
ASH Is the Most Important Conference for Myeloma Patients and Doctors
There is no other single conference where so much information is presented about myeloma. Information about so many topics is provided: how to treat MM patients in various stages; results of phase II & III trials which may indicate upcoming FDA approvals; pre-clinical research focusing on myeloma targets and cell understanding; and more. Soon I’ll be […]